My main area of expertise involves the use of the yeast Pichia pastoris expression system as a platform for recombinant protein development. My research focuses primarily on the original design, efficient expression and improved function of novel recombinant immunotoxins for development of targeted recombinant protein drugs. Since 2008, I have served as the Technical Director of the DF/HCC-MGH Recombinant Protein Expression and Purification Core Facility responsible for the administrative, scientific, and educational activities of the core. Under my supervision, we have successfully completed more than 50 recombinant protein expression and purification projects for DF/HCC and MGH investigators. Of particular relevance to the cancer research, we have successfully developed species specific IL-2 fusion toxins (murine, human and porcine) effective for in vivo depletion of IL-2 receptor positive cells, including regulatory T cells. We have also developed anti-porcine CD3 immunotoxin for in vivo depletion of porcine CD3 cells and porcine CTLA-4 fusion toxin for in vivo depletion of porcine CD80/CD86 cells.